There were no between-group differences seen on the planned secondary assessment analyses at 90 days , including the Barthel Index > or = 95 at 12 weeks ( last observation carried forward : placebo 40 % ; citicoline 40 % ) or mortality rate ( placebo 18 % ; citicoline 17 % ) .
